Progression-Free Survival is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumor Clinical Trials

BACKGROUND: The use of overall survival (OS) as the gold standard primary endpoint (PEP) in metastatic oncologic randomized controlled trials (RCTs) has declined in favor of progression-free survival (PFS) without a complete understanding of the degree to which PFS reliably predicts for OS. METHODS:...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Cancer
Päätekijät: Pasalic, Dario, McGinnis, Gwendolyn J., Fuller, C. David, Grossberg, Aaron J., Verma, Vivek, Mainwaring, Walker, Miller, Austin B., Lin, Timothy A., Jethanandani, Amit, Espinoza, Andres F., Diefenhardt, Markus, Das, Prajnan, Subbiah, Vivek, Subbiah, Ishwaria M., Jagsi, Reshma, Garden, Adam S., Fokas, Emmanouil, Rödel, Claus, Thomas, Charles R., Minsky, Bruce D., Ludmir, Ethan B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7702022/
https://ncbi.nlm.nih.gov/pubmed/32702645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.06.015
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia